Skip to main content

Advertisement

Table 4 Regimens used for salvage therapy, per country

From: Management and treatment of relapsed or refractory Ph(−) B-precursor ALL: a web-based, double-blind survey of EU clinicians

Regimen Number of respondents, na,b
  France Germany Italy Spain UK Total, n (%)
N = 15 N = 15 N = 15 N = 15 N = 15 N = 75
Published regimens
 Augmented hyper-CVAD 3 1 2 5   11 (15)
 CALGB 8811/Larson 1 1 1    3 (4)
 EORTC ALL-3 (induction phase) 1   2    3 (4)
 FLAG-AMSA   1    1 2 (3)
 FLAG-IDA   1   2 6 9 (12)
 GMALL 07/03   6 1    7 (9)
 GRAALL 02/2005 (salvage phase) 2 1     3 (4)
 GRAALL 2003 (salvage phase) 1 2     3 (4)
 Hyper-CVAD   1 1 1 1 4 (5)
 MRC UK ALL XII/ECOG 2993    1   3 4 (5)
 PETHEMA ALL-96     2   2 (3)
Modified published regimens
 FLAG-IDA     1 2 3 (4)
  1. aRespondents could select multiple guidelines regimens
  2. bPublished regimens reported by one respondent were: EORTC ALL3 (salvage); GIMEMA 0288 (induction phase); GIMEMA 0288 (salvage); GIMEMA-LAL0904 (induction phase); GIMEMA-LAL0904 (salvage); GRAALL 02/2005 (induction phase); LALA-94; nelarabine/cyclophosphamide; PALG 5–2007 (Induction II); VANDEVOL; modified published regimens reported by one respondent were: aBFM; augmented hyper-CVAD; CALGB 8811/Larson; GRAALL 02/2005 (induction phase); LALA-94; MRC UK ALL XII/ECOG 2993; PETHEMA ALL-96; RWGALS – NP1 (Induction I); VANDEVOL; ongoing clinical trials reported by one respondent were: NCT01564784 and UKALL 2011 trial
  3. aBFM, augmented Berlin-Frankfurt-Muenster; ALL, acute lymphoblastic leukaemia; CALGB, Cancer and Leukemia Group B; CVAD, cyclophosphamide, vincristine, doxorubicin (Adriamycin), dexamethasone; ECOG, Eastern Cooperative Oncology Group; EORTC, European Organization for Research and Treatment of Cancer; FLAG-AMSA, fludarabine, high-dose cytarabine, granulocyte colony-stimulating factor-amsacrine; FLAG-IDA, fludarabine, high-dose cytarabine, granulocyte colony-stimulating factor-idarubicin; GIMEMA, Gruppo Italiano Malattie EMatologiche dell’Adulto (Italian Group for Haematological Diseases in Adults); GMALL, German Multicenter Study Group for Adult ALL; GRAALL, Group for Research in Adult Acute Lymphoblastic Leukemia; LALA, Leucémie Aiguës Lymphoblastique de l’Adulte (Acute Lymphoblastic Leukemia in Adults); MRC UKALL XII, Medical Research Council Acute Lymphoblastic Leukemia Trial XII; PALG, Polish Adult Leukemia Group; PETHEMA, Programa para el Estudio de la Terapéutica en Hemopatía Maligna (Program for Study and Treatment of Malignant Hemopathies); RWGALS-NP1, Romanian Working Group for Acute Leukemia Study National Protocol 1; VANDEVOL, etoposide, clofarabine, asparaginase, mitoxantrone, and dexamethasone